Indication
Peripheral Nerve Injuries
4 clinical trials
3 products
1 drug
Product
NTX-001Clinical trial
Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to SOC in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring Below the Distal Border of the Brachial Plexus Requiring Surgical Repair.Status: Active (not recruiting), Estimated PCD: 2023-08-15
Clinical trial
A Phase 2a Multicenter Randomized Controlled Trial Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) Compared to Standard of Care in the Repair of Mixed Motor-sensory Acute Peripheral Nerve Injuries (PNI) for Rapid and Immediate Improvement in OutcomeStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury (PNI)Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve InjuryStatus: Recruiting, Estimated PCD: 2025-12-01
Product
TesamorelinDrug
Varlilumab